Better Understand the Symptoms and Care Options for Irritable Bowel Syndrome 2021 Enduring Material

This CME Enduring Material activity will provide physicians and mid-level providers a good foundation of the symptoms, diagnostic approaches and treatment therapies for chronic idiopathic constipation) patients with irritable bowel syndrome with diarrhea (IBS-D)and IBS-C (constipation). Special emphasis will be placed on the exploration of newly approved agents and those on the horizon of clinical practice. Key topics to be discussed include the diagnosis of IBS, the safety and efficacy of recently approved pharmacologic agents, and optimizing treatment and patient management approaches.

Welcome to On-line version of the Better Understand the Symptoms and Care Options for Irritable Bowel Syndrome Seminars. The content represents the most up-to-date information on the diagnostic approaches and treatment therapies for chronic idiopathic constipation) patients with irritable bowel syndrome with diarrhea (IBS-D) and IBS-C (constipation).

This course consists of one module offering 1.0 credit hour. During the course you will watch and listen to a video presentation.
 When you have viewed the presentation, you will be directed to take the required CME quiz, evaluate the seminar, and claim your Continuing Education credits.

Target Audience

Gastroenterologists, Internists, Hepatologists, family physicians, clinical pharmacists as well as related advanced-practice clinicians and nurse specialists. 

Joint Provider Statement
 This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Louisville and SC Liver Research Consortiun. The University of Louisville is accredited by the ACCME to provide continuing education for physicians.

Designation Statement
 The University of Louisville Office of Continuing Medical Education & Professional Development designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses - This program has been approved by the Kentucky Board of Nursing for 1.2 continuing education credits through University of Louisville Hospital, provider number 4-0068-12-22-1226. The Kentucky Board of Nursing approval of an individual nursing education provider does not constitute endorsement of program content. Completion criteria to obtain CE's: Attend entire session and complete the evaluation.

Course Instructions 
This online CME activity has been developed by the University of Louisville School of Medicine Continuing Medical Office. This course consists of one module offering 1.0 credit hour. During the course you will watch and listen to a video presentation.

  • You will have to register and create a user profile before you are able to view the material.
  • Once you have finished viewing the material you can either close the presentation window or select the CME Publisher Portal window at the top of the screen to continue with your post-test, evaluation, and generation of your CME certificate.
  • If you are not able to complete a module in one sitting you will be able to re-access the material once you have registered for the course. CLICK HERE on the module registration link and sign in, then Click Registration History from the menu at the left of the page to continue the activity.


Disclosures
As a provider accredited by the ACCME, the Office of CME&PD, School of Medicine, University of Louisville, must ensure balance, independence, objectivity, and scientific rigor in all its accredited educational activities. All Planners, faculty, reviewers, and other persons that affected the content of this CME activity were required to submit a financial disclosure form from which relevant conflicts of interest were determined. If any relevant financial relationship(s) with ineligible companies were disclosed, the materials each of them prepared for this program (or influenced) were peer-reviewed and determined to be without ineligible company bias, were considered fair and balanced in terms of therapeutic options, and presented evidence-based content. All relevant financial relationships with ineligible organizations have been mitigated prior to this activity.

Fouad J. Moawad, MD - Course Director, Planner; has no relevant financial relationships to disclose.
Howard J. Horwitz, MPH - Course Coordinator, Planner; has no relevant financial relationships to disclose.
Paul Pockros, MD - Planner; Speaking: Intercept, Gilead, AbbVie; Consulting: Intercept, Gilead, AbbVie, Prometheus; Contracted Research: Gilead, CymbraBay, Intercept.
Brooks Cash, MD - Planner, Faculty; Speaking Fees: Salix, Allergan, Sumergu Prometheus, Takeda; Consulting Fees: Salix, Allergan, Sumergu Prometheus, IM Health Sciences; Contracted Research Funding: Prometheus
Lisa Pfitzer, MD - Content Reviewer; has no relevant financial relationships to disclose.
Tracy Ander, DO - Content Reviewer; has no relevant financial relationships to disclose.
The University of Louisville CME & PD Advisory Board and Office Staff have nothing to disclose with the following Board Member exceptions: Sathya Krishnasamy, MD - Novo Nordisk, Kowa (Grant Funding);  Ashlee Bergin, MD – Merck (Speaking);  Michael Sowell, MD – Amgen, Abbvie, Biohaven, Teva, Lundbeck (Speaking); Rainer Lenhardt, MD - CSL Behring (Speaking).

Hardware & Software Requirements
High speed internet connection
Browser: Google Chrome is recommended

Original Release & Termination Dates
Course Originally Released On: 10/1/ 2021
Date of Most Recent Review: 9/27/2021
Course Termination Date: 10/1/2023

Special Services
If you need special accommodations due to a disability, or for an alternative form of course materials, please contact Howard Horwitz. Continuing Medical Education & Professional Development fully complies with the legal requirements of the ADA and the rules and regulations thereof.

Provider Contact Information
If you need technical support or have questions about the course, please e-mail us at cmepd@louisville.edu

Privacy Policy
The University of Louisville's Continuing Medical Education and Professional Development office respects your privacy. Personal information collected from participants of our medical educational activities will not, unless required by law, be shared with any third party. The primary reason we collect your personal information is for accountability and documentation of your continuing education activities in compliance with Accreditation Council for Continuing Medical Education (ACCME) regulations. We do not distribute unsolicited e-mails, nor, unless required by law, do we share the names of our subscribers with any third party.

Copyright
The University of Louisville has obtained permission to use the content in this educational activity.

Disclosure of Support from Ineligible Companies
This Internet Activity Enduring Material is Supported by educational grants from Salix and Abbvie.

Course Learning Objectives
As a result of participating in this activity, participants should be able to:
1. Explore the pathways and symptoms of those with Irritable Bowel Syndrome with Diarrhea and Constipation.
2. Summarize the underlying physiologic and psychological determinants of IBS symptoms.
3. Identify patients with CIC, IBS-C and IBS-D who are appropriate candidates for pharmacotherapy.
4. Review the diagnostic criteria and available tests.
5. Investigate behavioral approaches to address the stressors that may increase IBS symptoms and ways to minimize the effect.
6. Develop individualized treatment plans for patients with IBS and CIC by applying new clinical data.
7. Explore sucrase isomaltase (SI) deficiency and its similar symptoms to IBS-D.
8. Assist patients and their families to recognize the causes and treatments for IBS so they can partner with clinicians to manage symptoms and treatment - especially important for younger patients.
9. Review the benefits, efficacy, safety and mechanism of action of the most current FDA approved treatment options and OTC options.
10. Recognize when to refer patients to GI specialists and what therapeutic options may be available.

Registration

Fees
There is no fee to participate in this CME course.
TO REGISTER AND BEGIN THE COURSE   CLICK HERE
If you exit the activity before completion please select CLICK HERE in the registration option above then login and Click Registration History from the menu at the left of the page to continue the activity.

Content Questions and Comments
All participants are invited to submit their questions or comments about the content or cases in the presentations to
Questions will be routed to the faculty expert for reply and each will be answered within 48 hours of receipt.

This Course is Jointly Provided By